Levicitam 250 coated tablets 250 mg. №30

$36.00

Manufacturer: Ukraine

Monotherapy (first choice drug) for treatment: partial seizures with or without secondary generalization in adults and adolescents over 16 years of age who were first diagnosed with epilepsy. As an additional therapy for treatment: partial seizures with or without secondary generalization in adults and children with a body weight of 7 kg, patients with epilepsy (in this dosage form); myoclonic seizures in adults and adolescents over 12 years of age with juvenile myoclonic epilepsy; primary generalization of convulsive (tonic-clonic) seizures in adults and adolescents older than 12 years, patients with idiopathic generalized epilepsy.

Category:

Description

Levicitam Composition:

active substance: 1 tablet contains levetiracetam 250 mg or 500 mg
excipients: microcrystalline cellulose, copovidone, crospovidone, pregelatinized corn starch, magnesium stearate, coating for coating Opadry II White (polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide (E 171)).

Levicitam Dosage form.

Film-coated tablets.

Levicitam Pharmacotherapeutic group.

Antiepileptic drugs. Levetiracetam ATC code N03A H.

Clinical characteristics.

Levicitam Indications.

partial seizures with or without secondary generalization in adults and children over 16 years of age who are first diagnosed with epilepsy.

partial seizures with or without secondary generalization in adults and children over 4 years old with epilepsy
myoclonic seizures in adults and children over 12 years old with juvenile myoclonic epilepsy
primary generalized convulsive (tonic-clonic) seizures in adults and children over 12 years of age, patients with idiopathic generalized epilepsy.
Contraindications

Hypersensitivity to levetiracetam or other pyrrolidone derivatives, as well as to any components of the drug children under 4 years of age (safety and efficacy of the drug have not been established) elderly patients (from 65 years) severe liver dysfunction, renal failure.

Method of administration and dosage.

The tablets are taken orally with a sufficient amount of liquid, regardless of the meal. The daily dose is divided into two equal doses.

* children weighing up to 25 kg are prescribed levetiracetam in a different dosage form with the possibility of a lower dosage

for children weighing more than 50 kg, the dosage is carried out according to the scheme given for adults.

Since levetiracetam is excreted from the body by the kidneys, when prescribing the drug to patients with renal insufficiency and elderly patients, the dose should be adjusted depending on the level of creatinine clearance (CC).

Based on the concentration of serum creatinine, the CC for men can be calculated using the formula:

QC for women can be calculated by multiplying the resulting value by a factor of 0.85.

Adverse reactions.

The most common adverse reactions include:

from the psyche: agitation, depression, emotional instability, mood changes, hostility, aggressiveness, insomnia, nervousness, irritability, hallucinations, psychotic disorders, suicide, suicide attempts and suicidal thoughts
from the liver and biliary tract: liver failure, hepatitis. The drug affects the results of liver function tests
on the part of the hearing organs and vestibular apparatus: dizziness
on the part of the organs of vision: diplopia, loss of clarity of vision
on the part of skeletal muscles and connective tissue: myalgia
wounds, intoxication and complications: accidental injuries
infections and invasions: infectious diseases, nasopharyngitis